MedTrace Logo

Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma

NCT00591058 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2009-07-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and biologically active dose of TM-601 in adult patients with recurrent malignant glioma.

Conditions

Interventions

DRUG

TM-601

TM-601, administered intravenously (IV), once/week for 3 weeks

Sponsors & Collaborators

  • TransMolecular

    lead INDUSTRY

Principal Investigators

  • Burt Nabors, MD · University of Alabama at Birmingham

  • Glenn Lesser, MD · Wake Forest University

  • Steven Rosenfeld, MD, PhD · Columbia University

  • Sean Grimm, MD · Northwestern University

  • Maceij Mrugala, MD · University of Washington at Seattle

  • Jeremy Rudnick, MD · Cedars-Sinai Medical Center

  • Gerry Linette, MD · Washington University at St. Louis

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591058 on ClinicalTrials.gov